Humira (adalimumab) / AbbVie 
Welcome,         Profile    Billing    Logout  
 200 Diseases   191 Trials   191 Trials   20188 News 


«12...164165166167168169170171172173174...208209»
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Clinical, Retrospective data, Journal:  Clinical features and therapy of uveitis in childhood (Pubmed Central) -  Oct 17, 2019   
    13 children with severe disease activity required biological therapy (adalimumab injection)...Orv Hetil. 2019; 160(34): 1335-1339.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Journal:  Possible role of BMP-4 in the hyper-pigmentation of psoriatic plaques after anti-TNF-α treatment. (Pubmed Central) -  Oct 17, 2019   
    Tyr, BMP-4 and melanin content were also evaluated in the psoriatic lesional skin of patients receiving adalimumab therapy, before and after 16 weeks of treatment...The present study confirmed the influence of the psoriatic pro-inflammatory network on melanogenesis, exerting an inhibitory effect mediated by TNF-α. Furthermore, the results regarding BMP-4 in the present study add another important element to the mechanism of psoriasis.
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Humira (adalimumab) / Eisai, AbbVie
    Journal:  Ixekizumab superior to adalimumab for PsA. (Pubmed Central) -  Oct 17, 2019   
    Furthermore, the results regarding BMP-4 in the present study add another important element to the mechanism of psoriasis. No abstract available
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
    Clinicopathologic Spectrum of Renal Lesions Following Anti-TNF Alpha Inhibitor Therapy: A Single-Center Experience (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_4592;    
    In addition, active or chronic thrombotic microangiopathy was noted in 5, possibly associated to scleroderma or antiphospholipid antibodies, and nephrotic syndrome secondary podocytopathy in 2 cases. Conclusion The renal lesions during anti-TNF alpha therapy may have an autoimmune basis such as lupus, lupus-like or ANCA mediated disease, as well as secondary to endothelial or podocyte injury or related to the primary underlying systemic disease.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Tubulointerstitial Nephritis and Uveitis Unmasked by Decreasing Anti-TNF Alpha (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_4105;    
    Case Description 55-year-old Caucasian male with history of hypertension on lisinopril and psoriatic arthritis on adalimumab admitted for acute renal failure...He was also initiated on prednisone for concerns of acute interstitial nephritis...Discussion In patient with TINU, uveitis can present as vision loss without apparent inflammation, and it often presents separately from interstitial nephritis. This patient has atypical posterior uveitis and biopsy-proven AIN consistent with TINU, likely unmasked by tapering of adalimumab.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    TNF-α Inhibition Protects Against Renal Tubulointerstitial Injury Associated with Suppressing NLRP3 Inflammasome in Diabetic Rats (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_3949;    
    STZ-induced diabetic rats were treated with a TNF-α inhibitor (Humira) for twelve weeks...Moreover, TNF-α inhibition decreased expression of tubular IL-6 and IL-17A, which could activate NLRP3 inflammasome. Conclusion TNF-α inhibitor can protect against tubulointerstitial injury associated with suppressing NLRP3 inflammasome in diabetic rats.
  • ||||||||||  Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
    Not So Stellar: IgA Nephropathy Secondary to Immunotherapy Treatment for Psoriasis (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_1766;    
    He was treated with adalimumab,but became ineffective and it was changed to Ustekinumab...Ustekinumab was discontinued, and he was started on prednisone 60 mg PO daily and losartan 50 mg po daily...Nephrologists should be suspicious of the relationship of this agent and IgAN. It is important to diagnose early to ensure adequate treatment to minimize long term kidney complications.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
    IgA Nephropathy in Patients with Psoriatic Arthritis: A Case Series and Systematic Review of the Literature (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_1739;    
    She was treated with prednisone and recovered kidney function after 20 days...She was treated with steroids and cyclophosphamide, with improvement to eGFR 22 mL/min...There is heterogeneity in these patients’ presentations, treatments, and outcomes. Conclusion Further study is warranted to determine whether there is a pathophysiological link between IgAN and PsA.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / Eisai, AbbVie
    Tocilizumab-Induced Immune Complex Glomerulonephritis in a Patient with Rheumatoid Arthritis (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_1506;    
    Three years ago, the biologic was switched from adalimumab to TCZ...After discontinuing TCZ and MTX, intravenous methylprednisolone was administered at a dose of 500 mg/day for three days and then prednisolone (PSL) was initiated at 60 mg/day...The mechanism remains unknown because only one case of TCZ-induced IC-GN has been reported to date. Rheumatologists and nephrologists should be aware of this lesion and similar cases should be collected in future.
  • ||||||||||  Journal:  Biologic therapies in ulcerative colitis: primi inter pares? (Pubmed Central) -  Oct 13, 2019   
    Other factors, including convenience and satisfaction for the patient, route of administration, the cost of treatment, and the safety and efficacy profile, should all be considered. The aim of this review is to discuss the data from randomized controlled trials (RCTs) of available biological agents for the treatment of moderate-to-severe UC in adults, in order to support clinical decision making.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Journal:  Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. (Pubmed Central) -  Oct 12, 2019   
    Regarding the Lachnospiraceae family, in patients with normalization of C reactive protein six 6 months of adalimumab therapy, it increased from 16.6 ± 3.1% at T0 to 23.9 ± 2.6% at T1 (p = 0.049). In conclusion, in patients who respond to Adalimumab therapy by decreasing inflammation, there is a trend of intestinal eubiosis being restored.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Biomarker, Journal:  Serum cytokine, chemokine, and growth factor profiles and their modulation in inflammatory bowel disease. (Pubmed Central) -  Oct 11, 2019   
    Combined therapy of 5-ASA + Adalimumab produced significant upregulation of IL-4, IL-5, IL-15, and PDGF-BB. This information may be useful for deciding on the course of pharmacologic therapy for patients with IBD and for generating new therapy alternatives to improve the outcome of patients with IBD.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
    Retrospective data, Journal:  The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. (Pubmed Central) -  Oct 10, 2019   
    Cell-type enrichment analysis suggests that the gut mucosa and CD8 T cells are the main mediators of this response. Multimodality treatment, anti-TNFs use, and removal of setons after multimodality treatment can result in improved outcomes in CD patients with perianal fistulae and reduce the need for repeat surgery and radical surgery.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Journal:  Sunburn Recall Reaction and Mucositis Secondary to Methotrexate Toxicity. (Pubmed Central) -  Oct 10, 2019   
    Cutaneous examination revealed hemorrhagic crusting of upper and lower lips (Figure 2), scleral icterus, diffuse jaundice of the skin, and well-demarcated erythematous patches on mid-upper back and anterior neck. The patient had a few scattered erythematous papules with whitish center on bilateral extensor surfaces of the upper extremities and scattered petechiae on both the trunk and upper extremities.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Trial completion date:  OTIS Autoimmune Diseases in Pregnancy Project (clinicaltrials.gov) -  Oct 9, 2019   
    P=N/A,  N=554, Active, not recruiting, 
    This pharmacogenetic analysis identified genetic components that contribute to clinical responses to anti-rheumatic therapy. Trial completion date: Apr 2017 --> Dec 2019
  • ||||||||||  Journal:  Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists. (Pubmed Central) -  Oct 9, 2019   
    TNF-α antagonists are associated with an increased risk of opportunistic infection, although this risk has not been demonstrated conclusively in randomized controlled trials. Knowledge of concomitant risk factors, mechanism of infectious risk, and available treatment options can improve patient care in the clinical setting.